-
公开(公告)号：KR1020130079951A
公开(公告)日：2013-07-11
申请号：KR1020120000741
申请日：2012-01-03
Applicant: 서울대학교산학협력단
CPC classification number: C12Q1/6883 , C12Q2600/158 , G01N33/6893 , G01N2800/042 , G01N2800/164 , G01N2800/50 , G01N2800/60 , G01N33/5302
Abstract: PURPOSE: A marker for early diagnosis of diabetic retinopathy (DR) is provided to early diagnose DR and to significantly predict or understand DR progression by measuring and comparing the expression level of genes or proteins of which expression level is reduced in a patient with DR. CONSTITUTION: A composition for diagnosing DR contains an agent for measuring mRNA or protein level of one or more genes selected from the group consisting of prothrombin, apolipoprotein A1, alpha-2-macroglobulin, and complement factor H. A kit for diagnosing DR contains the composition. A method for providing information for diagnosing DR comprises the steps of: measuring the expression level of one or more genes or proteins selected from the group consisting of prothrombin, apolipoprotein A1, alpha-2-macroglobulin, and complement factor H; and comparing the expression level with the expression level of a control group sample.
Abstract translation: 目的：提供早期诊断糖尿病性视网膜病变（DR）的标志物，以早期诊断DR，并通过测量和比较DR患者中表达水平降低的基因或蛋白质的表达水平来显着预测或了解DR进展。 构成：用于诊断DR的组合物含有用于测量选自凝血酶原，载脂蛋白A1，α-2-巨球蛋白和补体因子H的一种或多种基因的mRNA或蛋白质水平的试剂。用于诊断DR的试剂盒含有 组成。 提供用于诊断DR的信息的方法包括以下步骤：测量选自由凝血酶原，载脂蛋白A1，α-2-巨球蛋白和补体因子H组成的组中的一种或多种基因或蛋白质的表达水平; 并将表达水平与对照组样品的表达水平进行比较。
-
公开(公告)号：KR101124039B1
公开(公告)日：2012-03-23
申请号：KR1020100086178
申请日：2010-09-02
Applicant: 서울대학교산학협력단
Abstract: 본 발명은 안와의 중심, 광 디스크의 중심, 제1 및 제2 주요 혈관에 근거하여, 혈관 면적(AUV) 및 분기 각도(MDA) 중 어느 하나 이상을 산출하여 비교함으로써 망막전막의 제거 전후의 망막의 정량적 특성을 산출할 수 있는 광학적 망막 특성 측정 장치에 관한 것이다.
-
公开(公告)号：KR1020120023902A
公开(公告)日：2012-03-14
申请号：KR1020100086178
申请日：2010-09-02
Applicant: 서울대학교산학협력단
Abstract: PURPOSE: An optical retinal property measurement apparatus is provided to compare blood vessel areas or branching angles by computing the blood vessel areas or the branching angles, thereby outputting quantitative retinal properties before and after performing an epiretinal membrane elimination process. CONSTITUTION: An eye-ground camera(110) records the bottom part of an eyeball. A first data storage device(120) stores a bottom part image of the eyeball. A blood vessel selection device(130) selects first and second major blood vessels. A second data storage device(140) two-dimensionally stores the first and second major blood vessels. A center detection device(150) determines the center of an optical disc or an eye socket. A quantitative retinal property calculation device calculates one or more among a blood vessel area and a branching angle.
Abstract translation: 目的：提供光学视网膜性质测量装置，通过计算血管面积或分支角来比较血管面积或分支角度，从而在进行视网膜消除过程之前和之后输出定量视网膜特性。 构成：眼睛相机（110）记录眼球的底部。 第一数据存储装置（120）存储眼球的底部图像。 血管选择装置（130）选择第一和第二主要血管。 第二数据存储装置（140）二维地存储第一和第二主要血管。 中心检测装置（150）确定光盘或眼窝的中心。 定量视网膜特性计算装置计算血管区域和分支角度中的一个或多个。
-
公开(公告)号：KR1020140043175A
公开(公告)日：2014-04-08
申请号：KR1020120108483
申请日：2012-09-28
Applicant: 서울대학교산학협력단
CPC classification number: G01N33/6893 , C12Q1/6883 , C12Q2600/118 , C12Q2600/158 , G01N33/15 , G01N2800/164
Abstract: The present invention discloses a protein differentially expressed in neovascular retinal diseases and the uses thereof. According to the present invention, ORP 150 or PGK 1 can be effectively used as targets of the development of therapeutic agents for various ophthalmic diseases involving the formation of new blood vessels, a therapeutic composition comprising the protein control agent, or a diagnostic kit for neovascular retinal diseases containing the protein or nucleic acid detection reagents, etc.
Abstract translation: 本发明公开了在新生血管性视网膜疾病中差异表达的蛋白质及其用途。 根据本发明，ORP 150或PGK 1可以有效地用作开发涉及形成新血管的各种眼科疾病的治疗剂的目标，包含蛋白质控制剂的治疗组合物或用于新生血管的诊断试剂盒 含有蛋白质或核酸检测试剂的视网膜疾病等
-
公开(公告)号：KR101343285B1
公开(公告)日：2013-12-18
申请号：KR1020120000742
申请日：2012-01-03
Applicant: 서울대학교산학협력단
Abstract: 본발명은당뇨망막병증(diabetic retinopathy) 진단용조성물및 당뇨망막병증진단용키트에관한것이다. 또한, 본발명은당뇨망막병증진단에필요한정보를제공하기위한분석방법에관한것이다. 상기에서기술한바와같이, 본발명은당뇨망막병증을조기에진단할수 있는마커를제공함으로써, 당뇨망막병증환자에게서발현이증가또는감소한유전자또는그 단백질의발현수준을측정및 비교하여당뇨망막병증의조기진단및 질병정도를유의적으로예측또는파악할수 있다. 아울러, 본발명의마커는비침습성진단을가능하게하는바, 혈액, 뇨검사등으로간단하고유효성있는당뇨망막병증의바이오마커를이용한진단방법이개발되면가정및 일반의원에서의조기발견에매우유용할것이며, 국가적인관점에서의료비절감효과를가지고올 수있다.
-
Patent Agency Ranking
公开(公告)号：KR1020130009205A
公开(公告)日：2013-01-23
申请号：KR1020110070123
申请日：2011-07-14
Applicant: 서울대학교산학협력단
CPC classification number: C12Q1/6883 , C12Q2600/158 , G01N33/68 , G01N2800/164 , G01N33/6893 , G01N33/5302 , G01N2800/042
Abstract: PURPOSE: A composition for diagnosing diabetic retinopathy containing an agent which measures gene or protein level of AGP(alpha-1 acid glycoprotein) or PEDF(pigment epithelium-derived factor) is provided to simply and early diagnose diabetic retinopathy. CONSTITUTION: A composition for diagnosing diabetic retinopathy contains an agent which measures mRNA or protein level of AGP or PEDF. A composition for diagnosing diabetic retinopathy contains an agent which measures mRNA or protein level of APOC1(apolipoprotein C1), APOB100(apolipoprotein B100), APOC3(apolipoprotein C3), APOB 100(apolipoprotein B100), APOC 3(apolipoprotein C3), CP(ceruloplasmin), or CFB(complement factor B). A method for providing information for diagnosing diabetic retinopathy comprises: a step of measuring gene or protein expression level of AGP or PEDF from a biological sample; and a step of comparing the expression level with the expression level of a normal control group.
Abstract translation: 目的：提供一种用于诊断糖尿病性视网膜病变的组合物，其用于测量AGP（α-1酸性糖蛋白）或PEDF（色素上皮衍生因子）的基因或蛋白质水平的试剂，以简单且早期诊断糖尿病性视网膜病变。 构成：用于诊断糖尿病性视网膜病变的组合物含有测量AGP或PEDF的mRNA或蛋白质水平的试剂。 用于诊断糖尿病视网膜病变的组合物含有测定APOC1（载脂蛋白C1），APOB100（载脂蛋白B100），APOC3（载脂蛋白C3），APOB 100（载脂蛋白B100），APOC 3（载脂蛋白C3），CP 血浆铜蓝蛋白）或CFB（补体因子B）。 提供用于诊断糖尿病性视网膜病变的信息的方法包括：从生物样品测量AGP或PEDF的基因或蛋白质表达水平的步骤; 以及将表达水平与正常对照组的表达水平进行比较的步骤。
-
公开(公告)号：KR1020130009204A
公开(公告)日：2013-01-23
申请号：KR1020110070122
申请日：2011-07-14
Applicant: 서울대학교산학협력단
CPC classification number: G01N33/6893 , G01N2800/042 , G01N2800/164 , C12Q1/6883 , G01N33/5302
Abstract: PURPOSE: A composition containing an agent which measures gene or protein level for determining development and progression of diabetic retinopathy is provided to enable non-invasive diagnosis and to early diagnose diabetic retinopathy. CONSTITUTION: A composition for diagnosing diabetic retinopathy contains an agent which measures mRNA or protein level of APOC1(apolipoprotein C1), APOB100(apolipoprotein B100), APOC3(apolipoprotein C3), VTN(vitronectin), PLG(plasminogen), HRP(histidine-rich protein), AFM(afamin) or CFB(complement factor B). A composition for diagnosing diabetic retinopathy additionally contains an agent which measures mRNA or protein level of AGP(alpha-1 acid glycoprotein), PEDF(pigment epithelium-derived factor), or CP(ceruloplasmin). The diabetic retinopathy is non-proliferative diabetic retinopathy. A method for providing information for diagnosing diabetic retinopathy comprises: a step of measuring gene or protein expression level of APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, or CFB from a biological sample; and a step of comparing the expression level with the expression level of a normal control group.
Abstract translation: 目的：提供一种含有测定基因或蛋白质水平以确定糖尿病性视网膜病变发展和进展的药物的组合物，以实现非侵入性诊断和早期诊断糖尿病性视网膜病变。 构成：用于诊断糖尿病视网膜病变的组合物含有测量APOC1（载脂蛋白C1），APOB100（载脂蛋白B100），APOC3（载脂蛋白C3），VTN（玻连蛋白），PLG（纤溶酶原），HRP（组氨酸 - 富含蛋白质），AFM（afamin）或CFB（补体因子B）。 用于诊断糖尿病性视网膜病变的组合物还含有测量AGP（α-1酸性糖蛋白），PEDF（色素上皮衍生因子）或CP（血浆铜蓝蛋白）的mRNA或蛋白质水平的试剂。 糖尿病性视网膜病变是非增殖性糖尿病性视网膜病变。 一种用于诊断糖尿病性视网膜病变的信息的方法，包括：从生物样品测量APOC1，APOB100，APOC3，VTN，PLG，HRP，AFM或CFB的基因或蛋白质表达水平的步骤; 以及将表达水平与正常对照组的表达水平进行比较的步骤。
-
公开(公告)号：KR101445930B1
公开(公告)日：2014-10-07
申请号：KR1020120108483
申请日：2012-09-28
Applicant: 서울대학교산학협력단
Abstract: 본원은 신생혈관성 망막질환에서 차별적으로 발현되는 단백질 및 그 용도를 개시한다. 본원에 따른 ORP 150 또는 PGK 1은 신생혈관의 생성이 수반되는 각종 안질환의 치료제 개발의 표적, 상기 단백질 조절제를 포함하는 치료용 조성물, 또는 상기 단백질 또는 그 핵산 검출시약을 포함하는 신생혈관성 망막질환 진단키트 등으로 유용하게 사용될 수 있다.
-
公开(公告)号：KR1020130079953A
公开(公告)日：2013-07-11
申请号：KR1020120000743
申请日：2012-01-03
Applicant: 서울대학교산학협력단
CPC classification number: C12Q1/6883 , C12Q2600/158 , G01N33/6893 , G01N2800/042 , G01N2800/164 , G01N2800/50 , G01N2800/60 , G01N33/5302
Abstract: PURPOSE: A marker for early diagnosis of diabetic retinopathy (DR) is provided to early diagnose DR and to significantly predict or understand DR progression by measuring and comparing the expression level of a gene or a protein of which expression is reduced in a patient with DR. CONSTITUTION: A composition for diagnosis of DR contains an agent which measures mRNA or protein level of one or more genes selected from the group consisting of alpha-1-acid glycoprotein 2, alpha-1-antitrypsin, apolipoprotein A2, apolipoprotein A4, beta-2-glycoprotein 1, and gelsolin. A kit for diagnosing DR contains the composition. A method for providing information for diagnosing DR comprises the steps of: measuring the expression level of one or more genes or proteins selected from the group consisting of alpha-1-acid-glycoprotein 2, alpha-1-antitrypsin, apolipoprotein A2, apolipoprotein A4, beta-2-glycoprotein 1, and gelsolin in a biological sample; and comparing the expression level with the expression level of a control group sample.
Abstract translation: 目的：提供早期诊断糖尿病性视网膜病变（DR）的标志物，以早期诊断DR，并通过测量和比较DR患者中表达降低的基因或蛋白质的表达水平来显着预测或了解DR进展 。 构成：用于诊断DR的组合物含有测定一种或多种选自下组的基因或蛋白质水平的试剂：α-1-酸糖蛋白2，α-1-抗胰蛋白酶，载脂蛋白A2，载脂蛋白A4，β- 2-糖蛋白1和凝溶胶蛋白。 用于诊断DR的试剂盒包含组合物。 提供用于诊断DR的信息的方法包括以下步骤：测量一种或多种选自α-1-酸 - 糖蛋白2，α-1-抗胰蛋白酶，载脂蛋白A2，载脂蛋白A4的基因或蛋白质的表达水平 ，β-2-糖蛋白1和凝溶胶蛋白; 并将表达水平与对照组样品的表达水平进行比较。
-
公开(公告)号：KR101216397B1
公开(公告)日：2012-12-31
申请号：KR1020090115528
申请日：2009-11-27
Applicant: 서울대학교산학협력단
Abstract: 서열번호 1 내지 105의아미노산서열을갖는단백질은 PDR 환자에서특이적으로과량발현되는것으로새롭게밝혀진단백질로서, 당뇨병성망막병증을검출할수 있는바이오마커로서사용될수 있다. 따라서, 상기바이오마커는당뇨병성망막병증과같은유리체망막(vitreoretinal) 질환을연구하는데기초적인정보를제공할수 있다. 특히, 상기새롭게밝혀진단백질은해당단백질과특이적으로결합하는분자, 예를들어모노클로날항체등과함께당뇨병성망막병증의진단을위한진단키트로제작될수 있다.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.027 seconds)
